Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease

Parkinson's disease involves both motor and non-motor symptoms like depression and anxiety that standard treatments do not fully address. Psilocybin, which acts on serotonin receptors, may help by modulating serotonin and dopamine systems, promoting neuroplasticity, and reducing brain inflammation. Evidence from depression and substance use disorders suggests psilocybin could improve both motor and non-motor symptoms, though direct clinical research in Parkinson's is lacking. Psilocybin's ability to increase brain network connectivity and regulate dopamine release provides a plausible mechanism. Ethical and regulatory hurdles remain, and future disease-specific trials are needed to determine efficacy, dosing, and safety.

Study at a glance

Abstract

Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor symptoms such as depression, anxiety, and cognitive impairment, which significantly affect patients' quality of life. Traditional dopaminergic therapies address motor symptoms but offer limited efficacy for neuropsychiatric manifestations. Psilocybin, a serotonergic compound with strong affinity for the 5-HT2A receptor, has emerged as a promising candidate for addressing the complex symptomatology of PD, including its neuropsychiatric components. This review examines the pharmacological effects of psilocybin, particularly its ability to modulate serotonergic and dopaminergic systems, enhance neuroplasticity, and reduce neuroinflammation, offering a potential therapeutic approach for PD. While clinical research in PD remains limited, evidence from related conditions such as Major Depressive Disorder (MDD) and Substance Use Disorder (SUD) supports the notion that psilocybin could modulate both motor and non-motor symptoms in PD. Furthermore, psilocybin’s ability to induce brain network hyperconnectivity and regulate dopamine release offers mechanistic insight into its potential benefits. Despite the promising neurobiological underpinnings, ethical concerns and regulatory constraints remain barriers to widespread clinical use. Future research should prioritize disease-specific trials to explore psilocybin’s therapeutic efficacy, optimal dosing, and safety profile in PD, potentially redefining the treatment landscape for this underserved population.